The updated sepsis diagnostic fraud analysis from Fact.MR forecasts significant growth for FY 2021-22 and beyond, with a market projected to expand at an annual rate of over 8 percent through 2032. The strong growth prospects were further fueled by the coronavirus pandemic, which spurred the rise of pneumonia-related sepsis and later led to death.
According to the analysis, the market is predicted to generate over US$ 1,630 Million in revenue by 2032, resulting in strong short-term benefits. These are mostly related to current R&D projects, as well as an increase in ICU and hospital admission-induced sepsis among patients. Manufacturers are adopting cutting-edge automated technology to provide accurate and rapid diagnosis.
Download Free Sample Copy of This Report – https://www.factmr.com/connectus/sample?flag=S&rep_id=391
Epidemiologically, an estimated 22 occurrences of paediatric sepsis and 2,202 instances of neonatal sepsis per 100,000 live births occur. This equates to 1.2 million instances of paediatric sepsis per year. According to the most recent estimates, an adult prevalence rate of 19.4 million sepsis episodes, with over 5 million fatalities, exists. As a result, efforts are being made to develop more complex sepsis diagnostic techniques, which are projected to increase demand in the future years.
Key Takeaways from the Market Study
- Global sepsis diagnostics market to more than double in value terms by 2032
- By product, demand for assays and reagents to reach US$ 300 Million in worth by 2032
- U.S to be an opportunistic market, expected to flourish at a 7.8% value CAGR
- Germany and India to register CAGRs worth 7% and 6.6% respectively
- China to yield a market value of US$ 750 Million by the end of the forecast period
- By 2022, global sepsis diagnostics market demand to reach US$ 755 Million
“As the frequency of hospital admissions for various diseases increases, risk of developing sepsis during treatment is rising, prompting healthcare settings to incorporate sepsis diagnostics and detection systems, spurring heightened R&D to introduce new solutions,” comments a Fact.MR analyst.
Prevalence of Sepsis in US widening Growth Opportunities
The American Centers for Disease Control and Prevention report that 1.7 million individuals in the US get septicemia each year, which results in almost 270,000 deaths. About one third of patients who die in hospitals die of septicemia.
US hospitals have an average duration of stay for sepsis patients of nearly 75 hours. By 2019, sepsis, severe sepsis, and septic shock took the lives of more than 50% of all people and cost roughly US$ 80,000 per person.
A succession of regulatory approvals in particular has helped broaden the market’s reach in recent times. For instance, in 2017, the Food and Drug Administration approved the prolonged use of the Brahms Vidas PCT Assay to evaluate how antibiotic therapies should be administered in pneumonia victims with sepsis. According to FactMR, the CAGR for sepsis diagnostics in the United States is expected to expand at more than 7.8 percent throughout the forecast period.
Get Customization on this Report for Specific Research Solutions – https://www.factmr.com/connectus/sample?flag=RC&rep_id=391
Competitive Landscape
The existence of a large number of diagnostic service providers peppers the global sepsis diagnostics market, making it extremely competitive. Among all of the expansion techniques used, providing technologically superior solutions through extensive R&D remains the primary goal.
- For example, Luminex Corporation, a diagnostics testing pioneer, provides the VERIGENE® and VERIGENE® II Systems, which are especially intended to target infections in the bloodstream, respiratory tract, and gastrointestinal tract. These technologies employ highly automated processes to aid in extraction, amplification, hybridization, and detection, therefore improving clinical outcomes by avoiding the start of sepsis.
- Similarly, Abionic SA provides the abioSCOPE, a non-fluidic immunoassay technique that was tested on hundreds of patients across 14 European hospitals, with doctors verifying that in more than 85 percent of instances, sepsis identification was achievable more than 24 hours prior to conventional care. In 2020, the solution was approved for clinical testing in hospitals across the United States.
Key Sepsis Diagnostics Service Providers
- BioMerieux SA
- Becton Dickinson and Company (BD)
- Thermo Fisher Scientific Inc.
- Abbott Laboratories Inc.
- Roche Holdings AG
For In-Depth Competitive Analysis, Buy Now – https://www.factmr.com/checkout/391
Key Segments Covered in the Sepsis Diagnostics Industry Report
- By Product :
- Blood Culture Media
- Instruments
- SAssays & Reagents
- By Method :
- Conventional
- Automated
- By Pathogen :
- Gram-Negative Bacterial
- Gram-Positive Bacterial
- Fungal
- Other Pathogens-based
- By Technology :
- Microbiology-based
- Molecular
- Immunoassays-based
- Other Technology-based
- By Region :
- North America
- Latin America
- Europe
- APEJ
- Japan
- Middle East & Africa
Check Out More Related Studies Published By Fact.MR Research:
Blood Cancer Diagnostics Market: In FY 2021, the blood cancer diagnostics market reached a valuation of US$ 15.05 Billion, and is likely to register a Y-o-Y growth rate of 5.6% in 2022, closing at US$ 15.95 Billion. Furthermore, across the 2022-2032 period of assessment, growth is expected to accelerate at a whopping 6.0% CAGR, reaching US$ 28.57 Billion.
Lung Cancer Diagnostics Market: The global lung cancer diagnostics market revenue to reach US$ 4 Bn by 2031, representing a 2x increase from 2020. Augmented development of lung cancer-specific biomarkers is propelling demand for the lung cancer diagnostics over the forecast period. Revenue from CA tests will account for US$ 1 Bn by 2031-end.
Ovarian Cancer Diagnostics Market: This global ovarian cancer diagnostics market analysis by Fact.MR predicts the industry to expand at a robust CAGR of 7% from 2021 to 2031. Fact.MR, a market research and competitive intelligence provider, has performed detailed analysis of the industry and researched all the factors that affect market growth. As per the study, the ovarian cancer diagnostics market amassed revenue worth US$ 1.3 Bn in 2020.
Breast Cancer Diagnostics Market: The global breast cancer diagnostics market is likely to acquire a market value of US$ 4 Bn in 2022 and is expected to register a CAGR of 7% by accumulating a market value of US$ 7.9 Bn in the forecast period 2022-2032.
Kidney Cancer Diagnostics Market: The global kidney cancer diagnostics market is projected to expand steadily at a CAGR 7% value, during the forecast period 2022-2032. In the year 2022, the market size is projected to expand and gain a global market valuation of US$ 800 Million. Considering this increasing growth and the booming demand in the global market, the kidney cancer diagnostics market is expected to reach US$ 1.4 Billion by 2032.
About Us:
Market research and consulting agency with a difference! That’s why 80% of Fortune 1,000 companies trust us for making their most critical decisions. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range – from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed. Our sales offices in United States and Dublin, Ireland. Headquarter based in Dubai, UAE. Reach out to us with your goals, and we’ll be an able research partner.
Contact:
US Sales Office:
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
Email: sales@factmr.com